Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will hold a conference call on December 10, 2018 to discuss the San Diego Superior Courts ruling related to Quidels BNP Supply Agreement with Beckman.
Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will host an investment community conference call beginning at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) on Monday, December 10th to discuss the outcome. During the conference call, management may answer questions regarding the intended ruling. Quidels responses to these questions, as well as other matters discussed during the conference call, may contain or constitute material information that has not been previously disclosed.
To participate in the live call by telephone from the U.S., dial 877-930-5791, or from outside the U.S., dial 253-336-7286, and enter the audience pass code 846-3868.
A live webcast of the call can be accessed on the Investor Relations section of the Quidel website (http://ir.quidel.com). The website replay will be available for 14 days. The telephone replay will be available for 48 hours beginning at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time) on December 10, 2018 by dialing 855-859-2056 from the U.S., or by dialing 404-537-3406 for international callers, and entering pass code 846-3868.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well-being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system. Marketed under the Sofia, QuickVue, D3 Direct Detection, Thyretain, Triage and InflammaDry leading brand names, as well as under the new Solana, AmpliVue and Lyra molecular diagnostic brands, Quidels products aid in the detection and diagnosis of many critical diseases and conditions, including, among others, influenza, respiratory syncytial virus, Strep A, herpes, pregnancy, thyroid disease and fecal occult blood. Quidel’s recently acquired Triage system of tests comprises a comprehensive test menu that provides rapid, cost-effective treatment decisions at the point-of-care (POC), offering a diverse immunoassay menu in a variety of tests to provide healthcare providers with diagnostic answers for quantitative BNP, CK-MB, d-dimer, myoglobin, troponin I and qualitative TOX Drug Screen. Quidels research and development engine is also developing a continuum of diagnostic solutions from advanced immunoassay to molecular diagnostic tests to further improve the quality of healthcare in physicians offices and hospital and reference laboratories. For more information about Quidels comprehensive product portfolio, visit quidel.com.
Media and Investors Contact: